341 related articles for article (PubMed ID: 32212813)
41. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
42. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
43. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Glisson BS; Murphy BA; Frenette G; Khuri FR; Forastiere AA
J Clin Oncol; 2002 Mar; 20(6):1593-9. PubMed ID: 11896109
[TBL] [Abstract][Full Text] [Related]
44. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
[TBL] [Abstract][Full Text] [Related]
45. Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer.
Wang HM; Lin CY; Hsieh CH; Hsu CL; Fan KH; Chang JT; Huang SF; Kang CJ; Liao CT; Ng SH; Yen TC
J Formos Med Assoc; 2017 Mar; 116(3):185-192. PubMed ID: 27133181
[TBL] [Abstract][Full Text] [Related]
46. Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Kim HR; Lee CG; Choi EC; Kim JH; Koh YW; Cho BC
Head Neck; 2016 Apr; 38 Suppl 1():E1653-9. PubMed ID: 26890965
[TBL] [Abstract][Full Text] [Related]
47. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
48. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
49. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
50. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Katori H; Tsukuda M
Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
[TBL] [Abstract][Full Text] [Related]
51. Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.
Specenier PM; Van Den Brande J; Schrijvers D; Huizing MT; Altintas S; Dyck J; Van Den Weyngaert D; Van Laer C; Vermorken JB
Anticancer Res; 2009 Dec; 29(12):5137-42. PubMed ID: 20044628
[TBL] [Abstract][Full Text] [Related]
52. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
[TBL] [Abstract][Full Text] [Related]
53. Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
Eswaran P; Azmi KS
J Cancer Res Ther; 2013; 9(3):392-6. PubMed ID: 24125972
[TBL] [Abstract][Full Text] [Related]
54. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
55. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
56. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
57. Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Schultz JD; Bran G; Anders C; Sadick H; Faber A; Hörmann K; Sauter A
Oncol Rep; 2010 Nov; 24(5):1213-6. PubMed ID: 20878112
[TBL] [Abstract][Full Text] [Related]
58. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Yang WC; Chen CH; Tang JY; Wu CF; Liu YC; Sun Y; Lin SF
Anticancer Res; 2014 Jul; 34(7):3765-73. PubMed ID: 24982400
[TBL] [Abstract][Full Text] [Related]
59. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
